Actively Recruiting
Radioimmunotherapy in Solid Tumors (PNRR-MCNT2-2023-12378239-Aim2)
Led by IRCCS San Raffaele · Updated on 2025-06-08
30
Participants Needed
1
Research Sites
130 weeks
Total Duration
On this page
Sponsors
I
IRCCS San Raffaele
Lead Sponsor
E
European Commission
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a prospective multicenter study of hypofractionated radiotherapy for the radiation treatment (RT) of solid tumors and in particular for Glioblastoma (in Aim 2). It is based on the results of ongoing studies at our Institute to validate the efficacy of extremely hypofractionated RT in neoadjuvant settings, which observed immunostimulatory effects of RT and the synergy with immune components. The collaboration between San Raffaele Hospital (Milan), the IRCCS Istituto Nazionale dei Tumori Fondazione G. Pascale (Naples) and the San Giuseppe Moscati Hospital of National Relief and High Specialty (Avellino) will ensure that patient recruitment, treatment and monitoring can be translated into facilities of the National Health System using common procedures. The various departments involved will treat patients with the same methods synergistically exploring the immuno/biological factors related to efficacy (and/or toxicity), based on new radioimmunotherapeutic approaches. Clinical and research activity will be developed jointly, drawing on the expertise in radiotherapy, radiomics, oncology, imaging and immunotherapy skills already available.
CONDITIONS
Official Title
Radioimmunotherapy in Solid Tumors (PNRR-MCNT2-2023-12378239-Aim2)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of Glioblastoma
- ECOG performance score 0-2 (defined during the first visit)
- Surgically removable lesion according to Neurosurgery Unit operability criteria
- Healthy volunteers will be recruited with sex and age comparable to patients for comparison
You will not qualify if you...
- Previous stroke
- Presence of another primary and/or metastatic tumor
- Healthy volunteers must have no primary or metastatic tumor
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
IRCCS San Raffaele Scientific Institute
Milan, MI, Italy, 20132
Actively Recruiting
Research Team
N
Nadia G Di Muzio, Prof
CONTACT
A
Andrei Fodor, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here